• The global Gabapentin market was valued at US$ 2,145.3 million in 2024 and is projected to reach US$ 3,875.6 million by 2032, reflecting a CAGR of 7.6% during the forecast period (2024-2032). Historically, the market stood at US$ 1,586.6 million in 2022, showcasing steady growth driven by increased diagnoses of neurological conditions and expanding applications of Gabapentin.
Email: help@intelmarketresearch.com +91 9169164321
• Gabapentin is a pharmaceutical drug primarily used to treat neurological disorders such as epilepsy and neuropathic pain. It functions by affecting nerve signals in the brain and spinal cord, helping to manage seizures and chronic pain conditions. Gabapentin is commonly available in capsule, tablet, and oral solution forms and is frequently prescribed for conditions like restless legs syndrome and postherpetic neuralgia.
Email: help@intelmarketresearch.com +91 9169164321
•Capsules
•Tablets
Epilepsy
Neuropathic Pain
Restless Legs Syndrome (RLS)
Others
Pfizer
Assertio Therapeutics
TEVA Pharmaceuticals
Mylan
Novartis
Apotex
Sun Pharmaceutical
Aurobindo Pharma
